Modality
ADC
MOA
IL-13i
Target
BTK
Pathway
NF-κB
HSRSVWet AMD
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
Dec 2019
→ Feb 2029
Phase 3Current
NCT07723007
721 pts·Wet AMD
2021-08→2029-02·Recruiting
NCT03591911
1,697 pts·HS
2019-12→TBD·Not yet recruiting
2,418 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-242.9y awayPh3 Readout· Wet AMD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2029-02-24 · 2.9y away
Wet AMD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07723007 | Phase 3 | Wet AMD | Recruiting | 721 | CR |
| NCT03591911 | Phase 3 | HS | Not yet recr... | 1697 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |